Overview

Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
To determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on disease progression in advanced colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborator:
Genentech, Inc.
Treatments:
Bevacizumab
Fluorouracil
Folic Acid
Leucovorin
Levoleucovorin
Oxaliplatin